Roivant Sciences ROIV Cash Flow Statement
| TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | ||
|---|---|---|---|---|---|---|
| —— | -$955.47M-82.4% | -$523.69M+17.9% | -$637.58M-99.9% | -$318.93M-379% | ||
| $3.35M-19.0% | $4.14M-35.0% | $6.37M-38.1% | $10.29M-26.9% | $14.07M-21.3% | ||
| $346.17M-1.8% | $352.48M+6.4% | $331.17M+3.2% | $321.02M+11.1% | $289.03M+14.6% | ||
| $3.42M+126% | -$12.9M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $7.42M-4.3% | $7.75M-4.1% | $8.09M-4.0% | $8.42M-3.8% | $8.76M+258% | ||
| -$1.01M-79.1% | -$562.75K-379% | -$117.5K-136% | $327.75K-57.6% | $773K+4,647% | ||
| —— | -$23.42M-168% | -$8.73M-202% | $8.58M+328% | -$3.76M— | ||
| $85.05M+38.8% | $61.27M+63.4% | $37.5M+173% | $13.72M+236% | -$10.05M-98.8% | ||
| —— | $143.87M+42.5% | $100.96M+385% | $20.84M-62.2% | $55.19M— | ||
| $8.28M-1.3% | $8.38M+10.8% | $7.57M+5.0% | $7.21M+5.3% | $6.84M+2.6% | ||
| —— | —— | —— | —— | -$8.85M-33.3% | ||
| -$2.39M-1.4% | -$2.35M+34.3% | -$3.58M+17.9% | -$4.36M+23.5% | -$5.7M+25.3% | ||
| -$11.46M— | —— | —— | —— | —— | ||
| -$750.35M+1.2% | -$759.1M+1.4% | -$769.86M+9.5% | -$851.01M-1.4% | -$839.45M-8.3% | ||
| —— | —— | $14.52M+89.3% | $7.67M+66.8% | $4.6M+11.2% | ||
| —— | —— | —— | —— | —— | ||
| $2.52M+39.2% | $1.81M+53.3% | $1.18M+114% | $550.5K+797% | -$79K+99.0% | ||
| $0-100% | $1.02B-50.0% | $2.03B-33.3% | $3.05B-25.0% | $4.06B+33.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $853.14M-34.0% | $1.29B+29.6% | ||
| $0-100% | $217.17M+121% | $98.35M+254% | $27.79M— | $0— | ||
| $0— | $0-100% | $112K-74.8% | $445K-42.5% | $774K-29.4% | ||
| —— | —— | —— | -$746.95M+38.8% | -$1.22B-17.0% | ||
| $3.77M— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $1.49M-50.0% | $2.98M-33.3% | $4.47M-25.0% | $5.96M-15.3% | ||
| —— | $45.26M-31.2% | $65.81M-18.8% | $81.02M+15.8% | $69.96M+28.8% | ||
| -$47.7M-42.1% | -$33.58M— | —— | —— | —— | ||
| —— | $143.87M+42.5% | $100.96M+385% | $20.84M-62.2% | $55.19M— | ||
| $0— | $0— | $0— | $0-100% | $110.39M— | ||
| —— | —— | —— | —— | $376.51M+33.3% | ||
| $3.42M+126% | -$12.9M— | —— | —— | —— | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| $770.24M+33.3% | $577.68M+50.0% | $385.12M+100% | $192.56M— | $0— | ||
| -$2.39M-1.4% | -$2.35M+34.3% | -$3.58M+17.9% | -$4.36M+23.5% | -$5.7M+25.3% | ||
| -$11.46M— | —— | —— | —— | —— | ||
| $15.59M+33.3% | $11.7M— | —— | —— | —— | ||
| $8.28M-1.3% | $8.38M+10.8% | $7.57M+5.0% | $7.21M+5.3% | $6.84M+2.6% | ||
| —— | —— | -$33.18M-258% | -$9.27M-146% | -$3.76M+91.0% | ||
| —— | —— | —— | —— | —— | ||
| $2.52M+39.2% | $1.81M+53.3% | $1.18M+114% | $550.5K+797% | -$79K+99.0% | ||
| $0-100% | $1.02B-50.0% | $2.03B-33.3% | $3.05B-25.0% | $4.06B+33.3% | ||
| $1.12B+33.3% | $841.73M+50.0% | $561.15M+100% | $280.58M— | $0— | ||
| —— | —— | —— | —— | $110.39M-92.1% | ||
| $0— | $0-100% | $112K-74.8% | $445K-42.5% | $774K-29.4% | ||
| $48.62M+2.7% | $47.33M+47.4% | $32.1M-5.8% | $34.08M-8.4% | $37.22M-36.2% | ||
| $193.61M-25.0% | $257.99M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0— | $0-100% | $48.98M-3.0% | $50.48M-2.9% | $51.98M-12.4% | ||
| $0-100% | $23.29M0.0% | $23.29M— | $0-100% | $11.65M+200% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $57.69M+33.3% | $43.26M— | —— | —— | —— | ||
| $31.11M+33.3% | $23.34M+50.0% | $15.56M+100% | $7.78M— | $0— | ||
| -$758.56M+1.1% | -$766.86M+2.2% | -$784.38M+8.7% | -$858.67M-1.7% | -$844.05M-8.3% | ||
| -$758.56M+1.1% | -$766.86M+2.2% | -$784.38M+8.7% | -$858.67M-1.7% | -$844.05M-8.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Roivant Sciences generate?
- Roivant Sciences (ROIV) generated -$750.3M in operating cash flow over the trailing twelve months.
- What is Roivant Sciences's free cash flow?
- After $14.0M of capital expenditures, Roivant Sciences's free cash flow was -$758.6M over the trailing twelve months, up 10.1% year over year.
- Where does Roivant Sciences's cash flow data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
